|
gptkbp:instanceOf
|
gptkb:protein
gptkb:anticoagulant
|
|
gptkbp:administeredBy
|
intravenous injection
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
B02BD08
|
|
gptkbp:brand
|
NovoSeven
Sevenfact
|
|
gptkbp:CASNumber
|
179372-44-4
|
|
gptkbp:category
|
hemostatic agent
|
|
gptkbp:contraindication
|
hypersensitivity to active substance
|
|
gptkbp:discoveredIn
|
1990s
|
|
gptkbp:halfLife
|
2-3 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
recombinant factor VIIa
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Novo_Nordisk
Hema Biologics
|
|
gptkbp:mechanismOfAction
|
activates the extrinsic pathway of coagulation cascade
|
|
gptkbp:molecularWeight
|
50 kDa
|
|
gptkbp:producedBy
|
gptkb:Chinese_hamster_ovary_cells
recombinant DNA technology
|
|
gptkbp:proteinSequence
|
identical to human factor VIIa
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
fever
allergic reactions
thromboembolic events
|
|
gptkbp:UNII
|
N8VZ3F878A
|
|
gptkbp:usedFor
|
gptkb:hemophilia_B
gptkb:hemophilia_A
gptkb:acquired_hemophilia
treatment of bleeding episodes
bleeding in patients with inhibitors to factors VIII or IX
congenital factor VII deficiency
|
|
gptkbp:bfsParent
|
gptkb:Glanzmann_thrombasthenia
gptkb:factor_VIIa
|
|
gptkbp:bfsLayer
|
7
|